Managing Nabilone-Induced Dizziness

Assessment and Risk Factors

• The American Geriatrics Society recommends that nabilone should be decreased or discontinued when patients experience persistent dizziness that affects daily functioning, particularly in older adults or those with a history of falls 1, 2
• Nabilone has a high incidence of dizziness or drowsiness as a common adverse effect, according to the American Geriatrics Society 1, 2
• Dizziness, vertigo, and postural hypotension are well-documented side effects that may necessitate dose reduction or discontinuation, as reported by the British Journal of Anaesthesia 3, 4
• Older adults are particularly vulnerable to nabilone-induced dizziness and postural hypotension, as noted by the American Geriatrics Society 1, 2
• Concurrent use of other CNS depressants or medications that cause orthostatic hypotension may increase the risk of dizziness, according to the British Journal of Anaesthesia 3

Dose Reduction and Management

• The American Geriatrics Society recommends immediate dose reduction when moderate to severe dizziness affects daily activities, or when there are episodes of falls or near-falls related to dizziness 1, 2
• The British Journal of Anaesthesia suggests considering dose reduction when mild but persistent dizziness lasts more than 3 days, or when patients report difficulty with mobility due to dizziness 3
• The National Comprehensive Cancer Network recommends reducing the dose from 1mg twice daily to 1mg once daily at bedtime, or reducing by 50% and reassessing for patients on higher doses 5, 6

Special Populations and Monitoring

• The American Geriatrics Society recommends starting with lower doses (0.5mg daily) and monitoring closely for dizziness in older adults, and reducing the dose at the first sign of dizziness 1, 2
• The British Journal of Anaesthesia suggests monitoring blood pressure regularly and reducing the dose if orthostatic changes occur in patients with cardiovascular conditions 3
• The Journal of Clinical Oncology recommends assessing orthostatic vital signs before and after initiating nabilone therapy, and educating patients to report dizziness promptly 6

Alternative Approaches and Important Caveats

• The National Comprehensive Cancer Network suggests considering alternative pain management strategies if dizziness is problematic for patients using nabilone for pain 5
• The Journal of Clinical Oncology recommends avoiding abrupt discontinuation and tapering the dose gradually when discontinuing nabilone 6
• The American Geriatrics Society notes that the risk-benefit ratio should be carefully evaluated in each patient, particularly when used for off-label indications 1, 2